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Background: Data suggests that brain-derived neurotropic factor (BDNF) plays a   neuroadaptive 
role in addiction. Whether serum BDNF levels are different in alcohol or psychostimulants as a 
function of craving is unknown. Here, we examined craving and serum BDNF levels in persons 
with alcohol versus psychostimulant dependence. Our goals were to explore BDNF as an objec-
tive biomarker for 1) craving 2) abstinence, and 3) years of chronic substance use.
Methods: An exploratory, cross-sectional study was designed. Men and women between 
20–65 years old with alcohol, cocaine, or methamphetamine dependence were eligible. 
A craving questionnaire was used to measure alcohol, cocaine and methamphetamine   cravings. 
Serum levels of BDNF were measured using enzyme linked immunoassay. Analysis of variance, 
chi-square, and correlations were performed using a 95% confidence interval and a significance 
level of P , 0.05.
Results: We found a significant difference in the mean craving score among alcohol, cocaine 
and methamphetamine dependent subjects. There were no significant influences of race, gen-
der, psychiatric disorder or psychotropic medication on serum BDNF levels. We found that 
among psychostimulant users BDNF levels were significantly higher in men than in women 
when the number of abstinent days was statistically controlled. Further, a significant correla-
tion between serum BDNF levels and the number of abstinent days since last psychostimulant 
use was found.
Conclusion: These data suggest that BDNF may be a biomarker of abstinence in psycho-
stimulant dependent subjects and inform clinicians about treatment initiatives. The results are 
interpreted with caution due to small sample size and lack of a control group.
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Introduction
Addiction is a progressive disease characterized by chronic use often initiated from 
substance craving and eventual relapse.1 Persons with addictions may also use chroni-
cally to alleviate withdrawal symptoms. During stages of withdrawal, neurobiological 
changes occur in dopamine, serotonin, and gamma-aminobutyric acid (GABA)-
  containing neuron systems.2–4 Neurotrophic factors are important neurobiological 
ligands involved in the development of addiction to drugs and alcohol.
Cerebral brain-derived neurotropic factor (BDNF) is an important modifier of 
neurogenesis, synaptic plasticity, cognitive functioning, and memory.5,6 Changes in 
BDNF expression in serotonergic and dopaminergic neurons have been found in patho-
logical behaviors.7–9 BDNF seems to influence neuronal differentiation of long-term 
potentiation and neurotransmission in those with psychostimulant and alcohol Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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dependence.10–12 Preclinical research shows that repeated 
cocaine administration increases BDNF expression in medial 
prefrontal cortical tissue.13 In rodent self   administration 
models, an injection of BDNF into the ventral tegmental 
area (VTA) following cocaine administration increases drug 
seeking behaviors and self-administration.14,15 In humans, 
peripheral serum BDNF levels appear to be significantly cor-
related with early alcohol withdrawal   severity.16 In addition, 
preclinical models have demonstrated that peripheral serum 
BDNF levels are correlated with BDNF centrally, specifically 
in cortical regions.17 Taken together, these data suggest that 
BDNF plays a strong neuroadaptive role in the development 
of addiction to drugs or alcohol.
However, it is still unclear as to whether serum BDNF 
levels may differentiate alcohol and psychostimulant use in 
a clinical population or serve as a biomarker of substance 
use or craving. Here, we examined the relationship between 
substance craving and serum BDNF levels in persons with 
alcohol or psychostimulant dependence, specifically cocaine 
or methamphetamine. Our primary goals were to explore 
BDNF as an objective biomarker for 1) self-reported craving 
intensity, 2) current substance use defined as the number of 
abstinent days since last use, and 3) substance use history 
defined as the number of years of chronic use.
Methods
study design
A prospective proof-of-concept, cross-sectional study was 
designed to explore serum BDNF as a biomarker for current 
craving, abstinence, and years of chronic use in alcohol versus 
psychostimulant dependent subjects. The study was conducted 
between September 2009 and May 2010 in an outpatient, 
community-based setting. In accordance with the Declara-
tion of Helsinki, Institutional Review Board approval by the 
University of North Texas Health Science Center in Fort Worth 
was obtained. In addition, a Certificate of Confidentiality was 
issued by the National Institute of Health to protect this vulner-
able sample. Participants received a $50 gift card after success-
fully completing all study assessments and procedures.
Participants
Volunteers were recruited through pamphlets and adver-
tisements placed in local community-based social service 
agencies providing counseling and addiction treatment. All 
volunteers had adequate opportunities to ask researchers 
questions about the study during the consenting process and 
make an informed decision whether or not to participate. 
All eligible subjects provided written informed consent to 
participate in the study and received copies of the consent 
form and the Certificate of Confidentiality.
inclusion/exclusion criteria
Eligible participants were 20–60 years old, of all ethnicities, 
and met current Axis I Diagnostic and Statistical Manual 
of Mental Disorders-IV (DSM-IV) diagnosis for alcohol, 
cocaine, or methamphetamine dependence. Subjects were 
English-speaking and had at least an 8th grade education. 
Volunteers were excluded if they had any current co-morbid 
substance dependence other than alcohol, cocaine or meth-
amphetamine. Other exclusion criteria were those who had 
a brain injury or stroke, mental retardation, dementia, HIV/
AIDS, or those who tested positive for current alcohol or any 
drug use as demonstrated by a breathalyzer and a 12-panel 
urine drug screen (Redwood Toxicology Laboratory, Santa 
Rosa, California). Subjects were required to abstain from 
food and exercise for three to four hours prior to study 
participation.
clinical assessments
Once sociodemographic information was recorded, par-
ticipants were interviewed using the Mini-International 
Neuropsychiatric Interview (MINI) to confirm diagnoses and 
age of onset for lifetime mood and substance use disorders.18 
The MINI is based on Axis I DSM-IV diagnostic criteria and 
has an acceptable range of reliability for alcohol and drug 
dependence (a = 0.60 to 0.74) and for psychiatric disorders 
(a = 0.45−0.59).18 In addition to its reliability for both sub-
stance use and psychiatric disorders, the MINI was used for 
its brevity (15 minutes) which was more feasible for us to 
use in our community-based research sample than the time-
intensive Structured Clinical Interview for DSM-IV .
The 10-item Cocaine Craving Questionnaire-Brief  19 
was modified to measure subjective alcohol, cocaine and 
methamphetamine cravings. This instrument measures 
craving as the lack of control of using, the desire, intention, 
planning, and anticipation of using to quell withdrawal 
symptoms.19,20 This questionnaire is scored using a Likert 
scale from 1 to 7 with 1 representing ‘strongly disagree’ 
and 7 being ‘strongly agree’. Scores are additive. The 
maximum total score indicating severe cravings is 70 while 
a score of 10 indicates that no craving is present. This crav-
ing instrument was used due to its brevity, high internal 
reliability (α = 0.90) and concurrent validity.19 In addition, 
previous studies using this questionnaire found this instru-
ment highly effective in measuring methamphetamine and 
alcohol cravings.21,22Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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serum BDNF analysis
All testing and sample handling procedures were performed 
using standard bio-safety techniques and disposal require-
ments as required by the University of North Texas Health 
Science Center. Blood specimens were collected only from 
study participants who satisfied eligibility requirements 
and tested negative for all drugs and alcohol. Those who 
had negative toxicology results were allowed to give blood 
and continue participation in the study. Blood samples were 
taken between the hours of 9:30 am–10:30 am. Subjects 
were required to abstain from food or drink for a period of 
2–3 hours prior to providing blood samples.
Subjects were placed in a comfortable upright resting posi-
tion while venous blood samples (30 mL) were drawn from 
the antecubital vein into Vacutainer® (BD, Franklin Lakes, 
NJ) tubes using a butterfly syringe. Blood samples were then 
centrifuged at 1000 rpm for 5 minutes after collection and 
serum specimens were stored at −80 °C until immunoassays 
were performed. BDNF was measured according to directions 
of Promega BDNF Emax Immunoassay System Kit (Promega, 
Madison, WI, USA). The serum samples were analyzed 
together in duplicate batch runs to assure an acceptable range 
of intra-assay coefficient of variation (∼7.1%) was obtained. 
Serum BDNF levels are stated as the mean average with 
standard deviations reported in picograms per milliliter.
statistical analyses
Sociodemographic and clinical characteristics were determined 
using descriptive statistics, analysis of variance, and chi-square 
analyses, as appropriate. Alcohol, cocaine, and methamphet-
amine group comparisons of BDNF levels were made using 
analysis of variance. Pearson correlations were used to exam-
ine relationships among serum BDNF levels, craving, current 
days of abstinence, and the number of years of substance use. 
Covariates included age, gender, race, psychiatric disorder, and 
psychotropic medication use. All statistical analyses were per-
formed using SPSS version 17. The statistical program we used 
automatically deleted outliers during the analysis to prevent 
spurious results. A 95% confidence interval and a probability 
alpha of 0.05 were used to determine statistical significance. 
To correct for multiple comparisons, Tukey post-hoc analyses 
were conducted on significantly different grouping variables 
that were relevant to our primary goals.
Results
Participants
Volunteers (n = 105) with psychostimulant or alcohol depen-
dence were screened for study eligibility. Nine volunteers 
did not meet inclusion criteria. Ninety-six volunteers met all 
study criteria and provided written informed consent to 
participate. Out of those who provided written informed 
consent, 32 participants were unable to complete all study 
assessments. Sixty-four participants provided evaluable data. 
Sociodemographic characteristics are shown in Table 1.
sociodemographic and substance use 
variables
There were no significant differences in gender distribu-
tion among the three substance groups. However, there 
was a significant race difference as no African-American 
subjects used methamphetamines: χ2 (6, n = 64) = 19.44; 
P = 0.003. Age among the three subject groups significantly 
differed (F(2,61) = 11.83, P = 0.001). The age difference is 
reflected in the mean years of use among the substance 
groups (F(2,61) = 4.87, P = 0.006). To control for multiple 
comparisons, Tukey post hoc analyses showed that years 
of substance use significantly different between alcohol and 
methamphetamine (P = 0.012) and between alcohol and 
cocaine (P = 0.009). A near significant trend was noted in 
the mean number of abstinent days that differed among alco-
hol, cocaine, and methamphetamine groups (F(2,61) = 4.50, 
P = 0.056).
craving
Table 1 shows a significant difference in the mean crav-
ing score among the three substance groups (F(2,61) = 4.50, 
P = 0.015). To be more specific, we used Tukey post hoc 
comparisons and found a significant difference in craving 
between the alcohol and cocaine groups (P = 0.012). There 
were no statistical differences in craving between alcohol 
and methamphetamine (P = 0.756) or between cocaine and 
methamphetamine groups (P = 0.162). To examine the gen-
eral effect of demographic and clinical indices on craving we 
collapsed the substance groups and analyzed mean craving 
scores according to race, gender, psychiatric disorder and 
psychotropic medication groups. Table 2 shows no signifi-
cant demographic or clinical group differences in craving.
serum BDNF levels, sociodemographic 
and clinical indices
Table 2 shows that there was no significant influence of race, 
gender, psychiatric disorder or psychotropic medication on 
serum BDNF levels. There were no significant gender dif-
ferences in serum BDNF levels between men and women 
(F (1,62) = 3.36, P = 0.071). Serum BDNF   levels did not differ 
significantly among alcohol, cocaine, and   methamphetamine Neuropsychiatric Disease and Treatment 2011:7
Table 1 sample and substance use characteristics
Demographic variables Alcohol (N = 27) Cocaine (N = 22) Methamphetamine (N = 15) χ2 P
Percentage distributions N (%) N (%) N (%)
gender 0.166 0.944
  Men 21 (32.81) 17 (26.56) 11 (17.19)
  Women 6 (9.38) 5 (7.81) 4 (6.25)
race 19.44 0.003
  White 19 (29.69) 7 (10.94) 12 (18.75)
  Black 6 (9.38) 13 (20.31) 0
  Hispanic 2 (3.13) 2 (3.13) 2 (3.13)
  Asian 0 0 1 (1.56)    
Substance-related variables Mean (SD) Mean (SD) Mean (SD) F P
Years of use 28.667 (11.25) 29.409 (10.83) 18.33 (9.88) 4.87 0.006
Number of abstinent days 70.148 (45.94) 108.36 (58.104) 76.333 (68.856) 3.03 0.056
craving scores 35.15 (16.67) 22.05 (13.76) 31.60 (15.40) 4.50 0.015
serum BDNF pg/mL 2853.07 (2112.80) 3660.39 (2377.80) 3779.39 (2803.49) 1.02 0.366
Tukey post hoc comparisons
Substance-related variables (I) (J) Mean difference (I-J) Std. error P
Years of substance use Alcohol cocaine −0.74 3.10 0.969
Methamphetamine 10.33 3.48 0.012
cocaine Methamphetamine 11.08 3.62 0.009
craving scores Alcohol cocaine 13.10 4.43 0.01
Methamphetamine 3.55 4.97 0.76
cocaine Methamphetamine −9.55 5.17 0.16
Abbreviation: sD, standard deviation.
Table 2 BDNF levels and craving scores
Sample demographics Serum BDNF Craving scores
Mean (SD) F (P) Mean (SD) F (P)
gender 3.366 (0.071) 0.020 (0.890)
  Men (N = 49) 3644.12 (2456.36) 29.653 (14.94)
  Women (N = 15) 2379.92 (1859.61) 30.333 (20.60)
race 1.451 (0.237) 0.637 (0.594)
  White (N = 38) 3149.41 (2591.87) 31.42 (16.86)
  Black (N = 19) 3694.33 (2043.10) 25.79 (15.74)
  Hispanic (N = 6) 2790.89 (1310.22) 33.33 (15.36)
  Asian (N = 1) 7645.51 (0.00) 24.00 (0.00)
clinical indices
Psychiatric disorder 1.217 (0.303) 0.875 (0.422)
  None (N = 29) 3796.11 (2505.80) 28.14 (14.52)
  Bipolar disorder (N = 33) 3048.70 (2265.94) 31.94 (17.80)
  Major depression (N = 2) 1783.22 (1611.65) 19.00 (12.73)
Psychotropic medications 1.165 (0.331) 0.226 (0.878)
  None (N = 40) 3711.58 (2561.87) 30.38 (16.02)
  Antidepressant (N = 13) 2297.38 (1567.45) 27.17 (19.27)
  Antipsychotic (N = 9) 2970.02 (2395.86) 33.11 (15.74)
  Mood stabilizer (N = 2) 3838.19 (3477.60) 30.00 (16.97)
Abbreviations: BDNF, brain-derived neurotropic factor; sD, standard deviation.
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groups (F(2, 61) = 1.02, P = 0.366). We analyzed the influence 
race, gender, psychiatric disorder or psychotropic medication 
may have had on serum BDNF levels among the substance 
groups, but there were no significant differences (P $ 0.260). 
The mean serum BDNF level in methamphetamine abusers 
and the relationship with number of days’ abstinence was not 
significant (r = −0.503, P = 0.056). Similarly, BDNF levels 
in alcohol (r = −0.300, P = 0.128) and cocaine (r = −0.185, 
P = 0.409) abusers were not significantly related to the 
number of abstinent days. Thus, we collapsed the cocaine 
and methamphetamine groups and designated this combined 
sample as the psychostimulant group.Neuropsychiatric Disease and Treatment 2011:7
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Figure 1 correlations between the number of abstinent days and serum brain-derived neurotropic factor levels in alcohol, psychostimulant (cocaine and methamphetamine 
groups combined), cocaine, and methamphetamine abusers.
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serum BDNF levels in alcohol  
and psychostimulant groups
Although serum BDNF levels were lower in the alcohol 
group in comparison to the psychostimulant group, the 
difference was not significant (F(1,62) = 2.05, P = 0.157). 
However, a significant difference in serum BDNF levels 
between alcohol and psychostimulant groups emerged when 
the number of abstinent days prior to collecting serum BDNF 
was statistically controlled (F(1,61) = 4.31, P = 0.045). In addi-
tion, Figure 1 shows a significant correlation between serum 
BDNF levels and the number of abstinent days in the psycho-
stimulant group (r = −0.33, P = 0.044). Serum BDNF levels 
of alcohol, cocaine, methamphetamine, and the combined 
cocaine and methamphetamine group (ie, psychostimulant) 
are shown for visual comparison.
Discussion
Our research goals were to compare serum BDNF levels 
in persons with alcohol, cocaine and methamphetamine 
dependence to craving, abstinence, and years of use. Previ-
ous clinical and preclinical BDNF research have focused 
largely on the serum BDNF levels during periods of with-
drawal and post-withdrawal.16,23–26 Thus, we may be the 
first to show differences in BDNF levels among alcohol, 
cocaine, and methamphetamine use in relation to craving 
and abstinence. To that end, we found significant differences 
in BDNF levels between alcohol and psychostimulants as 
a function of abstinence. However, in terms of substance 
use history, we found no significant relationships between 
BDNF and years of chronic use of alcohol, cocaine or meth-
amphetamine. Statistically controlling for the presence of a 
psychiatric disorder, gender, age, and race did not change 
these results. Likewise, no significance relationships between 
BDNF and self-reported craving score for either alcohol, 
cocaine, or methamphetamine dependent groups emerged. 
Arguably, the inter- and intra-individual variability of self-
reported craving in alcohol and psychostimulant dependent 
populations may be considerable and transient. Thus, in this 
cross-sectional design a one-time measure of self-reported 
craving may not be a suitable variable to correlate with serum 
BDNF levels.
Many of our subjects had comorbid psychiatric and 
substance use disorders. There are few studies investigating 
differences in serum BDNF levels in those with or without 
comorbid Axis I disorders. One study investigated serum 
BDNF levels in schizophrenia subjects with and without 
substance abuse and in healthy controls.23 These results 
showed that serum BDNF levels in schizophrenia patients 
with co-morbid polysubstance abuse were higher compared 
to schizophrenia patients who did not abuse substances, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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or healthy controls. Although not significant, we found 
somewhat lower levels of BDNF levels in those who had 
comorbid bipolar or major depressive disorders versus 
those who were not mentally ill. Similarly, de Oliveira et al24 
examined serum BDNF levels in bipolar disorder patients 
who were medication-free, those receiving antipsychotics, 
antidepressants or mood stabilizers, and healthy controls.24 
This study reported significantly lower BDNF levels in all 
bipolar patients regardless of medication use in comparison 
to healthy controls.
While our study was not designed to examine medica-
tion effects per se, we nonetheless examined the effect that 
psychotropic medications may have had on BDNF levels and 
craving in those who were receiving psychotropic medica-
tions versus those who were medication free. We found 
BDNF levels were somewhat lower in those taking antide-
pressant medications although this effect was not statistically 
different. In contrast to our data, Aydemir et al25 who exam-
ined BDNF levels in pre- and 6-weeks post-medication con-
ditions in depressed women (n = 20) receiving S-citalopram 
found a significant increase in BDNF in the post-medication 
condition.
study limitations and strengths
The sample size in the present study may be small in com-
parison to some clinical trials. However, our sample is sub-
stantially larger than Huang et al16 who examined BDNF in 
persons with alcohol dependence (n = 47), Aydemir et al25 
who examined serum BDNF in depressed women (n = 20), 
or Angelluci et al26 who investigated serum BDNF in chronic 
cocaine and heroin abusers (n = 45). The available data is 
limited to only a handful of small clinical studies and much 
of the BDNF research is preclinical rodent studies. Thus, our 
data clearly augments the existing literature.
Another potential limitation is not having controlled for 
the duration, frequency of use, and average dose of alcohol 
or the psychostimulants among our subject population. 
While we acknowledge the importance and interest of these 
measures the ability to control for these variables would have 
been beyond the scope of this study. However, we were able 
to clarify the state of dependence as our subjects qualified for 
DSM-IV criteria for dependence which covers a 12-month 
period. Therefore under the rubric of DSM-IV dependence 
general frequency is implied for 12 months.
Another limitation of our study is the heterogeneity of our 
subject population. We did not have a healthy control group 
to compare BDNF levels to the alcohol and psychostimulant 
groups. We also did not exclude subjects based on   comorbities, 
endocrine disorders or class of   psychiatric   medication which 
are known factors that influence BDNF.27–30 In doing so, 
our enrollment goal would have been significantly reduced. 
Instead, our sample reflects the typical community-based 
outpatient that clinicians are most likely to encounter. Thus, 
our study has strong ecological validity producing data that 
may be helpful to health professionals and case managers.
concerning therapeutic approaches
As BDNF comparison studies between alcohol and psycho-
stimulant abusers are scarce, our primary goal was to con-
duct a proof-of-concept study to generate hypotheses and to 
investigate differences between alcohol and psychostimulant 
users. Thus, a control group was not needed. The statisti-
cally significant differences we found between alcohol and 
psychostimulant dependence serve to generate hypotheses 
rather than to support a particular theory. It would also be 
of interest to examine the effect of BDNF polymorphism on 
these data. The distribution of the BDNF-gene 66 ValMet 
polymorphism results in higher BDNF secretion centrally, 
and is associated with addiction to drugs and alcohol.31–33
There is a possibility that the relationship observed 
between serum BDNF and number of days abstinent may 
not be causally related to the induction of the neurobio-
logical substrates which underlie addiction. For example 
other underlying factors, such as inflammation, could have 
influenced BDNF in the periphery.34 However we excluded 
subjects with any kind of central nervous system diseases 
or impairments, as well as HIV/AIDS. Thus the likelihood 
of brain inflammation is limited. In addition, a number of 
researchers have suggested that peripheral BDNF concentra-
tions are associated with BDNF levels in the brain.35 Indeed, 
cerebral BDNF crosses the blood–brain barrier, is correlated 
with BDNF centrally in rodents, and is associated with a 
marker of neuronal integrity, N-acetylaspartate.17,36,37 As this 
was a proof-of-concept, hypothesis generating study, our 
data importantly indicate that serum BDNF has feasibility in 
clinical research of addiction and co-occurring disorders and 
should be further examined as a biomarker for psychostimu-
lant use and abstinence in future longitudinal research. The 
results from this study provide applicable substance group 
differences, thus a larger sample size with added controls in 
future research with BDNF is substantiated.
Conclusion
Serum BDNF levels in psychostimulant dependent subjects 
were significantly related to the number of abstinent days 
since last psychostimulant use. Psychostimulant dependent Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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subjects had significantly higher serum BDNF levels than 
those with alcohol dependence. Craving and substance use 
history was not related to serum BDNF levels. These data 
lend support to the idea that serum BDNF levels may be a 
biomarker of abstinence, particularly in cocaine and meth-
amphetamine dependence. While these data may inform 
clinicians, we interpret these results with caution.
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